Avidity Biosciences (RNA) has issued an update.
Avidity Biosciences has expanded its incentive plan, tripling the number of shares for issuance, and is hosting an investor event to discuss promising FORTITUDE™ trial results for their FSHD therapy, delpacibart braxlosiran. Initial trial data shows over 50% reduction in targeted genes and improved muscle function, with plans to initiate Phase 3 cohorts. Updates on other programs, including a Phase 3 trial for myotonic dystrophy and upcoming data for Duchenne muscular dystrophy treatment, signal a period of significant growth and development for the company.
See more data about RNA stock on TipRanks’ Stock Analysis page.
